offline
Teva shares surge 5% on news of patent settlement with Neos over ADHD drug
Shares of generic drug maker Teva Pharmaceuticals Industries Ltd. rose about 5% Wednesday on news of a settlement and licensing agreement with Neos Therapeutics Inc. to resolve a patent dispute about a treatment for attention deficit disorders, or ADHD.
Neos NEOS, -7.91% said the confidential agreement grants Teva TEVA, +5.79% the right to make and market its generic version of Cotempla XR-ODT under a TEVA Abbreviated New Drug Application starting July 1, 2026, or earlier under certain circumstances. Cotempla is an extended-release oral tablet used to treat the disorder, which affects about 4.4% of U.S. adults, according to the Attention Deficit Disorder Association.
...
https://www.marketwatch.com/story/teva-s...2018-12-26
![[Bild: TEVAc1dl1357.png]](https://finviz.com/publish/122618/TEVAc1dl1357.png)
Shares of generic drug maker Teva Pharmaceuticals Industries Ltd. rose about 5% Wednesday on news of a settlement and licensing agreement with Neos Therapeutics Inc. to resolve a patent dispute about a treatment for attention deficit disorders, or ADHD.
Neos NEOS, -7.91% said the confidential agreement grants Teva TEVA, +5.79% the right to make and market its generic version of Cotempla XR-ODT under a TEVA Abbreviated New Drug Application starting July 1, 2026, or earlier under certain circumstances. Cotempla is an extended-release oral tablet used to treat the disorder, which affects about 4.4% of U.S. adults, according to the Attention Deficit Disorder Association.
...
https://www.marketwatch.com/story/teva-s...2018-12-26
